A/Prof Rosemary Sutton

group manager

Senior researchers

BSc (ANU), MSc (Syd), PhD (Syd); Group Manager, Minimal Residual Disease (MRD)

Associate Professor Rosemary Sutton joined Children’s Cancer Institute in 2001. Since then, she has led the Minimal Residual Disease (MRD) diagnostic testing for over 2000 patients with acute lymphoblastic leukaemia (ALL) from Australia and New Zealand. Many of these patients were enrolled in MRD clinical trials for newly diagnosed and relapsed patients that required MRD testing. Others were patients with a high risk of relapse who needed MRD monitoring before and after stem cell transplantation or experimental therapies.

A/Prof Sutton's career as a molecular biologist has focussed on translational research with agricultural or medical applications. She has authored over 70 peer-reviewed journal articles, including more than 40 papers on leukaemia. Her current research focuses on clinical trial questions and improving the identification and outcomes for high risk ALL patients through collaboration with other scientists and clinicians in Australia and internationally.

She is a conjoint Associate Professor in the UNSW Faculty of Medicine.

Key publications

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.

Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R

Leukemia. 2013 Jul;27(7):1497-503. PMID: 23407458

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V

Lancet. 2010 Dec 11;376(9757):2009-17. PMID: 21131038

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion.

Venn NC, van der Velden VH, de Bie M, Waanders E, Giles JE, Law T, Kuiper RP, de Haas V, Mullighan CG, Haber M, Marshall GM, Md N, van Dongen JJ, Sutton R

Leukemia. 2012 Jun;26(6):1414-6. PMID: 22157735

Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease.

Karsa M, Dalla Pozza L, Venn NC, Law T, Shi R, Giles JE, Bahar AY, Cross S, Catchpoole D, Haber M, Marshall GM, Norris MD, Sutton R

PLoS One. 2013;8(10):e76455. PMID: 24146872

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.

Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children’s Oncology Group

Br J Haematol. 2009 Aug;146(3):292-9. PMID: 19500099

A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.

Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, Zhang J, Wei L, Wu G, Rusch M, Nagahawatte P, Ma J, Chen SC, Song G, Cheng J, Meyers P, Bhojwani D, Jhanwar S, Maslak P, Fleisher M, Littman J, Offit L, Rau-Murthy R, Fleischut MH, Corines M, Murali R, Gao X, Manschreck C, Kitzing T, Murty VV, Raimondi SC, Kuiper RP, Simons A, Schiffman JD, Onel K, Plon SE, Wheeler DA, Ritter D, Ziegler DS, Tucker K, Sutton R, Chenevix-Trench G, Li J, Huntsman DG, Hansford S, Senz J, Walsh T, Lee M, Hahn CN, Roberts KG, King MC, Lo SM, Levine RL, Viale A, Socci ND, Nathanson KL, Scott HS, Daly M, Lipkin SM, Lowe SW, Downing JR, Altshuler D, Sandlund JT, Horwitz MS, Mullighan CG, Offit K

Nat Genet. 2013 Oct;45(10):1226-31. PMID: 24013638

Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.

Szczepanski T, van der Velden VH, Waanders E, Kuiper RP, Van Vlierberghe P, Gruhn B, Eckert C, Panzer-Grümayer R, Basso G, Cavé H, Stadt UZ, Campana D, Schrauder A, Sutton R, van Wering E, Meijerink JP, van Dongen JJ

J Clin Oncol. 2011 Apr 20;29(12):1643-9. PMID: 21357790

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ, European Study Group on MRD detection in ALL (ESG-MRD-ALL)

Leukemia. 2007 Apr;21(4):604-11. PMID: 17287850

Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-kappa and heavy-chain gene rearrangements.

Sutton R, Bahar AY, Kwan E, Giles JE, Venn NC, Tran S, Hackenberg N, Pozza LD, Marshall GM, Haber M, van der Velden VH, Norris MD

Leukemia. 2008 Dec;22(12):2265-7. PMID: 18496559